Podcast

Tick-Derived Therapeutic Molecules With Akari Therapeutics' Rachelle Jacques

Source: Cytiva
22_01_BPO_BusBiotech_Social_ep123

Ticks are a scourge. They're vectors of multiple serious and debilitating diseases, and evolution has made them perfectly adept at attaching to their hosts—and potentially spreading those diseases virtually undetected— that ability owing to anti-inflammatory and anesthetic proteins in their saliva. But the emerging biotech Akari Therapeutics thinks there's a broad range of medicinal value in those proteins. They've painstakingly developed a recombinant version of one such tick saliva-derived protein, called nomacopan, and put it to work in phase 3 trials to treat rare but deadly severe hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). On this week's episode of the Business of Biotech, Akari President & CEO Rachelle Jacques tells us about the redeeming qualities of tick saliva and how her company is putting it to work.

          

 

 

 

 

LISTEN TO THE PODCAST!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online